Allogene Therapeutics, Inc.
ALLO
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The companā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$1.18
Price+12.38%
$0.13
1Y
Price
Market Cap
$261.805m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-
EBITDA Margin-
Net Profit Margin-
Free Cash Flow MarginRevenue
$0.00
-100.0%
1y CAGR-72.0%
3y CAGR-78.9%
5y CAGREarnings
-$236.908m
+8.0%
1y CAGR+11.1%
3y CAGR-13.4%
5y CAGREPS
-$1.11
+15.9%
1y CAGR+21.6%
3y CAGR-3.2%
5y CAGRBook Value
$344.561m
$470.593m
Assets$126.032m
Liabilities$79.241m
DebtDebt to Assets
16.8%
-0.3x
Debt to EBITDAFree Cash Flow
-$173.601m
+13.6%
1y CAGR+7.9%
3y CAGR+3.6%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company